May 25, 2023 4:05pm EDT Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 15, 2023 7:05am EDT Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
May 04, 2023 7:05am EDT Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Apr 24, 2023 4:15pm EDT Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
Mar 14, 2023 7:05am EDT Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
Mar 07, 2023 7:05am EST Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023
Feb 13, 2023 7:05am EST Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023
Jan 05, 2023 7:00am EST Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
